Stockscreener 앱 받기
3.835
3.33%
-0.165
Journey Medical Corp 주식(DERM)의 최신 뉴스
DFD-29: The Journey to FDA Approval and a New Era in Rosacea Management - Dermatology Times
LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register
Tillys Inc (TLYS): Major Improvements, Worth A Look - Stocks Register
Journey Medical (NASDAQ:DERM) Shares Down 5.3%Here's Why - MarketBeat
SWK Holdings Provides Portfolio Update - AccessWire
Malaysia’s education, business, healthcare AI journey in 2024 - The Malaysian Reserve
Bridgebio’s Attruby FDA nod boosts stock; 10 November approvals - BioWorld Online
One Man Shares His Journey With ATTR-CM - Health Central
Journey Medical Decline Means Insider Profits Down To US$101k - Simply Wall St
Journey Medical Co. (NASDAQ:DERM) Sees Large Increase in Short Interest - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Position in Service Properties Trust (NASDAQ:SVC) - Defense World
Walleye Capital LLC Takes $220,000 Position in The Taiwan Fund, Inc. (NYSE:TWN) - Defense World
GE HealthCare - linkedin
Injection Perfection Medical Spa Unveils Morpheus8 OptimasMax for Comprehensive Aesthetic Treatments. - StreetInsider.com
How we help consumers eat well and support their health - Danone
Our mission - Danone
Michelle Borland of Vital Strandz: The Journey to Becoming a Trusted Hair Loss Practitioner for Individuals in the USA - Yahoo Finance
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Journe - GuruFocus.com
Palmar Hyperhidrosis Pipeline Trends 2024: Clinical Trials, - openPR
Nahdi Medical Company solidifies its position as the largest primary healthcare provider in the Kingdom - ZAWYA
Journey Medical Corp (DERM) Should Be Considered For The Next Few Weeks - Stocks Register
AI Face Reshape Simulator: How It Transforms Med Spa Consultations - Perfect Corp.
One Behavioral Provider’s Decision to Co-Develop Technology - Healthcare Innovation
Women of Influence: Erica Conroy's journey from the lab to the C-SuiteColumbus Business First - The Business Journals
FY2024 EPS Estimate for Journey Medical Decreased by Analyst - MarketBeat
Hims & Hers Expands Nutrition Support to Fuel Customers’ Weight Loss Journeys - Yahoo Finance
FY2024 EPS Estimates for Journey Medical Boosted by B. Riley - MarketBeat
Showcasing the Journey of Researchers and Entrepreneurs at UP Manila’s Salinlohiya 2024 - University of the Philippines Manila
NY AI medical company wins global health tech competition at Scientific Sessions 2024 - American Heart Association
Journey Medical Co. (NASDAQ:DERM) Short Interest Down 20.7% in October - MarketBeat
Despite Journey Medical's Pullback, Insiders Still Gained US$118k - Yahoo Finance
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - Yahoo Finance
Topgolf Callaway Q3 Earnings & Revenues Top Estimates, Fall Y/Y - Yahoo Finance
Entero, Journey to merge, creating oncology-focused biopharma - Investing.com
Journey Medical Corp (DERM) Q3 2024 Earnings: Revenue Hits $14.6M, EPS Loss of $0.12 Beats Estimates - GuruFocus.com
Journey Medical earnings beat by $0.05, revenue topped estimates - Investing.com
Journey Medical Corporation (DERM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Runway Growth Finance Corp. (RWAY) Q3 Earnings and Revenues Lag Estimates - Yahoo Finance
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Reports Q3 Revenue $14.6M - Marketscreener.com
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - Yahoo Finance
Lost emperor penguin recovering after record journey across Southern Ocean - ABC News
Best travel insurance companies in 2024 - USA TODAY
FY2024 EPS Estimates for Journey Medical Raised by Analyst - MarketBeat
Q3 EPS Estimates for Journey Medical Reduced by Roth Capital - Defense World
FDA approves Journey Medical’s rosacea treatment Emrosi - Yahoo Finance
Journey gets FDA okay for Emrosi, releases preliminary Q3 earnings report (NASDAQ:DERM) - Seeking Alpha
US FDA approves Journey Medical's drug for long-term skin condition - Reuters
Journey Medical gains as US FDA approves skin condition drug - XM
Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea - Yahoo Finance
mWell says users gain access to 26 MPH hospitals - BusinessWorld Online
Seven PDUFA dates on FDA’s November calendar - BioCentury
Nahdi continues the growth journey with 9.0% yoy revenue increase and meeting the profitabilty guidance - ZAWYA
Biotech Stocks Facing FDA Decision In November 2024 - RTTNews
Journey Medical Co. (NASDAQ:DERM) Short Interest Update - MarketBeat
1.65%
2.76%
자본화:
|
볼륨(24시간):